Sharps Technology Planning To Collaborate With Roncadelle To Support Global Distribution And Sales Of High Quality, Innovative, Safer Drug Delivery Systems
- None.
- None.
The strategic alliance between Sharps Technology and Roncadelle Operations signifies an important development in the medical device sector, particularly in the area of drug delivery systems. The partnership is poised to enhance the companies' product distribution capabilities, leveraging an expanded network of North American third-party logistics (3PL) partnerships. This expansion into new markets could potentially increase market share and revenue streams for both entities.
From a market research perspective, the collaboration taps into a growing demand for innovative injection solutions, a market that is expected to expand significantly. This is driven by the increasing preference for injectable therapies across a range of medical applications, including vaccines, gene therapies and chronic disease management. The emphasis on safety and the prevention of needle stick injuries is particularly relevant given the heightened awareness of healthcare worker safety and public health concerns.
The alliance may also result in operational synergies, reducing costs and improving efficiency through shared technology and distribution channels. This could lead to competitive advantages over other players in the medical device industry, potentially impacting the stock performance of Sharps Technology in the medium to long term.
The partnership between Sharps and Roncadelle is set to impact the smart safety disposable syringe and prefillable syringe markets by combining their respective expertise in active and passive safety syringe technologies. Sharps' Securegard and Sologard product lines emphasize low-waste and ultra-low-waste technologies, which are significant in reducing medical waste and environmental impact. These features align with the World Health Organization's guidelines on re-use prevention, which is critical in preventing the transmission of diseases.
Roncadelle's SafeR Retractable Safety Syringe complements Sharps' offerings with its own passive safety systems, further enhancing the alliance's portfolio in terms of safety and patient protection. The collaboration could accelerate the development and distribution of these advanced medical devices, potentially leading to increased adoption rates and improved healthcare outcomes globally.
Furthermore, the expansion of manufacturing capabilities, such as Sharps' plans in the U.S., indicates a strategic move to localize production and could serve to mitigate risks associated with global supply chains, which is particularly relevant in the context of recent global events that have disrupted international logistics.
Sharps Technology's expansion of its 3PL distribution partnerships and alliance with Roncadelle Operations represents a strategic move to diversify and strengthen its global distribution network. This move could be seen as a response to the growing need for healthcare solutions that are not only effective but also safe and easy to use.
Financially, the partnership could lead to enhanced revenue growth for Sharps Technology as it gains access to new markets and broadens its product portfolio. The collaboration may also result in cost savings through shared resources and economies of scale. Investors should monitor the execution of this strategy and its impact on Sharps' financial performance, particularly in terms of sales growth, market penetration rates and profit margins.
However, it is important to consider the risks associated with such strategic alliances, including integration challenges and the potential for increased competition. Investors should also be aware of the capital expenditures associated with expanding manufacturing facilities and the time required for regulatory approvals in new markets, which could affect the short-term financial outlook.
Sharps and Roncadelle are Joining Forces to Supply Drug Delivery Systems to the International HealthCare Market Through an Expanded Network of North American 3PL Distribution Partnerships
NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: STSS) (NASDAQ: STSSW), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is working to create new sales and distribution opportunities through the addition of new North American 3PL partnerships to expand its reach into the global healthcare market. These additional third-party logistics partnerships, along with a developing alliance with Roncadelle Operations, a driving force in the development of safe, novel medical drug delivery devices, would combine the strengths and capabilities of the two companies to develop, market and distribute unique drug delivery solutions around the globe, capitalizing on a growing network of established and new logistics resources. Sharps and Roncadelle are evaluating their alliance as an opportunity to work together to bring new drug delivery solutions to market and pave the way to join the companies’ complementary product portfolios, expanding their global reach for both the smart safety disposable syringe and prefillable syringe markets. The partnership to sell and distribute each other’s product portfolio to their respective areas of influence will also move Sharps’ American-based product market into Europe, the Middle East, Africa and the Asia-Pacific region, as well as Roncadelle’s product reach into the North and South American healthcare markets.
Sharps Technology says the need for innovative injection solutions is expected to grow exponentially over the next several years as injectables are the first choice for therapies as diverse as vaccines, biologics, weight loss and maintenance, ophthalmic applications, gene therapies, diabetes and inflammatory disease management. Sharps Technology specializes in the development and manufacturing of innovative drug delivery systems. The company’s Securegard and Sologard product lines focus on low-waste and ultra-low-waste syringe technologies that incorporate active safety features as well as World Health Organization-accredited re-use prevention measures. These features protect frontline healthcare workers from life-threatening needle stick injuries and protect the public from the dangers of needle re-use. Sharps currently has a manufacturing facility in Hungary and is pursuing plans to expand its manufacturing capacity in the U.S. Based in Italy, Roncadelle Operations specializes in developing and manufacturing proprietary passive safety syringes. Their SafeR Retractable Safety Syringe and needles offer a passive safety system with auto-disable reuse prevention features. Additionally, as a Contract Development and Manufacturing Organization (CDMO), they also provide end-to-end services from design to finished products of innovative, safer medical drug delivery solutions.
Sharps reports that the synergy between Sharps and Roncadelle will bring together more than 30 established distribution points with Sharps’ new 3PL partnerships to deliver products to the world healthcare market that stand for simplicity of use and are unparalleled in safety and patient protection, setting new global standards to safeguard people from infection and disease. The business alliance additionally creates a very important player in advancing syringe market opportunities through the development of unique technologies such as prefilled syringes, needle guard systems, auto-injectors, and injector pen devices. “It is exciting to see how well our companies complement each other and how we can leverage our combined relationships, expertise, and resources to build out our distribution network, enhance syringe safety around the world, and introduce novel drug delivery solutions to the healthcare industry,” states Robert Hayes, Sharps CEO. “As we work through the network expansion and details of our collaboration, we can see that this is great timing and a perfect fit for both Sharps and Roncadelle.”
For more information on the companies, please visit http://sharpstechnology.com and www.roncadelle-operations.com.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements”. Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” “poised” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Investor Relations:
Dave Gentry
RedChip Companies, Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
STSS@redchip.com
FAQ
What is Sharps Technology, Inc.'s ticker symbol?
What is the main focus of the partnership between Sharps and Roncadelle Operations?
Where is Sharps Technology, Inc.'s manufacturing facility located?
What are the key product lines of Sharps Technology, Inc.?
What are the main products developed by Roncadelle Operations?
